Harbin Gloria Pharmaceuticals (002437) — Financial Flexibility Index
Harbin Gloria Pharmaceuticals (002437) has a Financial Flexibility Index of 0.22x as of September 2025. Free cash flow of CN¥187.15 Million (operating CF CN¥182.89 Million minus capex CN¥4.26 Million) represents 0% of total liabilities (CN¥852.18 Million). Also explore Harbin Gloria Pharmaceuticals (002437) net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Harbin Gloria Pharmaceuticals Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Harbin Gloria Pharmaceuticals across 19 annual periods. Check 002437 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year free cash flow to debt coverage for Harbin Gloria Pharmaceuticals. For the full company profile including market capitalisation, see Harbin Gloria Pharmaceuticals market capitalisation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | CN¥297.17 Million | CN¥273.36 Million | CN¥825.00 Million | ▼ -35.2% |
| 2024 | 0.56x | CN¥473.83 Million | CN¥410.94 Million | CN¥852.26 Million | ▲ +163.9% |
| 2023 | 0.21x | CN¥303.80 Million | CN¥274.18 Million | CN¥1.44 Billion | ▲ +69.5% |
| 2022 | 0.12x | CN¥294.63 Million | CN¥261.62 Million | CN¥2.37 Billion | ▲ +9.4% |
| 2021 | 0.11x | CN¥308.69 Million | CN¥274.18 Million | CN¥2.72 Billion | ▲ +420.3% |
| 2020 | 0.02x | CN¥56.43 Million | CN¥12.76 Million | CN¥2.58 Billion | ▼ -84.0% |
| 2019 | 0.14x | CN¥658.79 Million | CN¥610.37 Million | CN¥4.82 Billion | ▼ -45.2% |
| 2018 | 0.25x | CN¥1.27 Billion | CN¥1.16 Billion | CN¥5.08 Billion | ▲ +41.7% |
| 2017 | 0.18x | CN¥846.43 Million | CN¥651.80 Million | CN¥4.81 Billion | ▼ -33.7% |
| 2016 | 0.27x | CN¥1.23 Billion | CN¥1.04 Billion | CN¥4.62 Billion | ▲ +30.5% |
| 2015 | 0.20x | CN¥985.14 Million | CN¥702.05 Million | CN¥4.85 Billion | ▼ -53.7% |
| 2014 | 0.44x | CN¥799.93 Million | CN¥674.04 Million | CN¥1.82 Billion | ▼ -66.9% |
| 2013 | 1.33x | CN¥616.37 Million | CN¥453.02 Million | CN¥464.60 Million | ▼ -22.8% |
| 2012 | 1.72x | CN¥350.25 Million | CN¥205.89 Million | CN¥203.79 Million | ▼ -33.2% |
| 2011 | 2.57x | CN¥295.51 Million | CN¥128.61 Million | CN¥114.91 Million | ▼ -46.4% |
| 2010 | 4.79x | CN¥353.47 Million | CN¥112.59 Million | CN¥73.73 Million | ▲ +219.8% |
| 2009 | 1.50x | CN¥232.29 Million | CN¥170.82 Million | CN¥154.95 Million | ▲ +33.2% |
| 2008 | 1.13x | CN¥95.89 Million | CN¥57.81 Million | CN¥85.17 Million | ▲ +32.7% |
| 2007 | 0.85x | CN¥65.44 Million | CN¥52.26 Million | CN¥77.15 Million | — |